A double-blind comparison of the anxiolytic activity of two benzodiazepines, metaclazepam and bromazepam, in anxiety neurosis.

Abstract

A double-blind controlled trial was carried out in 50 patients with anxiety neuroses to compare the effectiveness of metaclazepam, a recently developed benzodiazepine with anxiolytic activity, and bromazepam. Patients were allocated at random to receive treatment for 13 days with either 15 mg metaclazepam or 4 mg bromazepam per day, in 2 divided doses. The patients' anxiety status was assessed on entry and after 7 and 13 days of treatment by the physician, using the Hamilton multi-factorial rating scale, and by the patients, using a self-assessment rating scale. Both drugs produced a highly significant reduction in mean total scores, improvement being evident by the Day 7 assessment. Correlation between scores on the two scales was significant at all time points. Metaclazepam, however, was rated as producing a significantly greater improvement from baseline than with bromazepam on the self-rating scale.

• Authors: F Bilone, R Roncari
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 11 Issue 1 Pg. 45-7 ( 1988) ISSN: 0300-7995 [Print] England
• PMID: 2898321 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Anxiety Agents
• Benzodiazepines
• metaclazepam
• Bromazepam

Topics

• Adult
• Aged
• Anti-Anxiety Agents (therapeutic use)
• Anxiety (drug therapy)
• Benzodiazepines (therapeutic use)
• Bromazepam (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Random Allocation